Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. Its transforming growth factor beta (TGFß) superfamily biology, its novel understanding of the molecular mechanisms of growth factor activation enabled us to develop a proprietary platform for development of monoclonal antibodies that locally and selectively target the precursor. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.

Period	PE Ratio
2018-12-31	N/A
2019-12-31	N/A
2020-12-31	-18.62
2021-12-31	-14.58
2022-12-31	-23.15
2023-12-31	-26.30
2024-12-31	-21.19
2025-12-31	-15.91

	A	B	C	D
1	Symbol	Price	Change	Volume
2	SRRK	$52.33	+2.07%	2.46M
3
4
5

Scholar Rock Holding Corporation (SRRK) PE Ratio

PE Ratio Data

Get Scholar Rock Holding Corporation Data in Excel

More SRRK Financial Data